Related Experiment Video
Updated: May 9, 2026

Direct Mouse Trauma/Burn Model of Heterotopic Ossification
Published on: August 6, 2015
Celecoxib and heterotopic bone formation after total hip arthroplasty
Carlos J Lavernia1, Juan S Contreras2, Jesus M Villa2
1Orthopaedic Institute at Mercy Hospital, Miami, Florida.
Insights
Celecoxib effectively prevents heterotopic ossification after total hip replacement. This short-term pain management option is safe and does not affect anticoagulation.
Area of Science:
- Orthopedic Surgery
- Pharmacology
Background:
- Heterotopic ossification (HO) is a common complication following total hip replacement (THR).
- Preventing HO can improve patient outcomes and reduce revision rates.
Purpose of the Study:
- To evaluate the efficacy of celecoxib in preventing HO after primary THR.
- To assess the safety and impact on anticoagulation of celecoxib in this patient population.
Main Methods:
- A prospective study of 170 consecutive primary THR patients.
- Patients received either celecoxib (200mg twice daily for 28 days) or no celecoxib post-surgery.
- HO incidence and severity (Brooker classification) were assessed at 3, 6, and 12 months.
Main Results:
- HO was significantly less common in the celecoxib group at all follow-up points (P < 0.01).
- Fewer celecoxib recipients developed moderate to severe HO (Brooker classes II/III) at 1 year.
- No celecoxib patients had severe HO (Brooker class IV), compared to 2% in the control group. No treatment discontinuations or aseptic loosening revisions occurred.
Conclusions:
- A short course of celecoxib aids in preventing HO after primary THR.
- Celecoxib is a safe and effective option for HO prevention post-THR.
- This treatment does not interfere with anticoagulation therapy.
Abstract:
We assessed the effectiveness of celecoxib in the prevention of heterotopic ossification (HO) following primary total hip replacement (THR). We studied 170 consecutive THRs. Sixty-three patients received celecoxib after surgery (200mg twice/daily) for 28 days and 84 did not. HO was more common in non-celecoxib patients than in the celecoxib-group at 3, 6, and 12 months (P =0.005, 0.004 and 0.01, respectively). At 1 year, fewer celecoxib recipients had Brooker classes II or III. None of the celecoxib patients developed HO Brooker class IV, while 2% in the non-celecoxib group did. No patient discontinued treatment or had revision for aseptic loosening. A short course of celecoxib for pain aids in the prevention of HO after primary THR, and could be a useful and safe option that does not interfere with anticoagulation.
Related Concept Videos
Bone Remodeling and Repair
Osteoclasts in Bone Remodeling
Bone Formation by Endochondral Ossification
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Fractures: Bone Repair
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the procedure...
Bone Formation by Intramembranous Ossification
The process begins when mesenchymal cells in the embryonic skeleton gather together and differentiate into osteogenic cells, which then develop into...
